Driving Advances in Liver Health: Tackling Current Challenges in Viral Hepatitis and NASH

Download All
In this video and accompanying downloadable slides, expert faculty discuss approaches to improve diagnosis and treatment of hepatitis C, hepatitis B, and NASH with an emphasis on how clinicians can maximize liver health.
Paul Y. Kwo, MD
Program Director
Manal F. Abdelmalek, MD, MPH
Oluwaseun Falade-Nwulia, MBBS, MPH
Paul Y. Kwo, MD

ClinicalThought

No therapies are FDA approved for NASH, but I believe metabolic, inflammatory, and fibrotic aspects of NASH will all shape its management.

Manal F. Abdelmalek, MD, MPH Released: October 4, 2019

Why the path to HCV elimination must reach PWID.

Oluwaseun Falade-Nwulia, MBBS, MPH Released: October 14, 2019

We must stay the course to eliminate HBV as a public health threat.

Paul Y. Kwo, MD
Program Director
Released: October 16, 2019

How long should patients with chronic hepatitis B be treated with nucleos(t)ide analogues? When should we treat patients with immune-tolerant hepatitis B? Here’s my take.

Paul Y. Kwo, MD Released: December 4, 2019

How can providers ensure that vulnerable populations are linked to HCV testing and care? Here’s my take on what we should be doing in our practice.

Oluwaseun Falade-Nwulia, MBBS, MPH Released: December 18, 2019

Here’s my take on bariatric surgery, noninvasive testing, and endpoints in patients with NASH.

Manal F. Abdelmalek, MD, MPH Released: January 16, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue